title: [Management of fungal urinary tract infections].
abstract: Fungal urinary tract infections (funguria) are rare in community medicine, but common in hospitals where 10 to 30% of urine cultures isolate Candida species. Clinical features vary from asymptomatic urinary tract colonization (the most common situation) to cystitis, pyelonephritis, or even severe sepsis with fungemia. The pathologic nature of funguria is closely related to host factors, and management depends mainly on the patient's underlying health status. Microbiological diagnosis of funguria is usually based on a fungal concentration of more than 10(3)/mm(3) in urine. No cutoff point has been defined for leukocyte concentration in urine. Candida albicans is the most commonly isolated species, but previous antifungal treatment and previous hospitalization affect both species and susceptibility to antifungal agents. Treatment is recommended only when funguria is symptomatic or in cases of fungal colonization when host factors increase the risk of fungemia. The antifungal agents used for funguria are mainly fluconazole and amphotericin B deoxycholate, because other drugs have extremely low concentrations in urine. Primary and secondary preventions are essential. The reduction of risk factors requires removing urinary catheters, limiting antibiotic treatment, and optimizing diabetes mellitus treatment.
authors.affiliation: Service des Maladies Infectieuses et Tropicales, Groupe de Recherche sur les Antimicrobiens et les Micro-Organismes [EA2656-IFR23], Centre Hospitalier Universitaire, Rouen, France. manuel.etienne@chu-rouen.fr
authors.forename: Manuel
authors.initials: M
authors.lastname: Etienne
authors.forename: François
authors.initials: F
authors.lastname: Caron
mesh_terms: D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002176:Candida albicans / Q000302:isolation & purification; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology; D003556:Cystitis / Q000382:microbiology; D003840:Deoxycholic Acid / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use; D016469:Fungemia / Q000175:diagnosis; D005658:Fungi / Q000302:isolation & purification; D006304:Health Status; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000401:mortality / Q000517:prevention & control; D011322:Primary Prevention; D011704:Pyelonephritis / Q000382:microbiology; D012307:Risk Factors; D014546:Urinary Catheterization / Q000009:adverse effects; D014552:Urinary Tract Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000401:mortality / Q000517:prevention & control; D014556:Urine / Q000382:microbiology
chemical_list: D000935:Antifungal Agents; D004338:Drug Combinations; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination; D015725:Fluconazole